Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

(Reuters) - U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for ...

While semaglutide remains on the shortage list, Novo Nordisk noted last week that the last remaining ... and that counterfeit forms of Ozempic are being sold. Semaglutide and a similar GLP-1 drug, ...

Sahpra warns against counterfeit GLP-1 products like Ozempic, citing health risks. Only registered products should be used; ...

A new study shows that Ozempic may help ease arthritis knee pain in people with obesity. Here's what to know about the study and whether semaglutide can truly help reduce knee pain, according to ...

The South African Health Products Regulatory Authority (SAHPRA) has expressed concern at the increasing presence of counterfeit Glucagon-like ...

A study reveals racial and ethnic disparities in access to Novo Nordisk's diabetes and weight loss drugs among U.S. military veterans. Black, Asian, and Native American patients are less likely to ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

In recent health news, Chinese scientists stress the need for regional diets to combat obesity, U.S. minority veterans ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...